.png)
.png)
.png)
Upload Prescription
.png)
.jpg)
1 strip = 10 tablet
ACME laboratories LtdProduct Description
Indications: Orbapin is indicated for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents to reduce blood pressure. It may be used as initial therapy in patients who are likely to require multiple drugs to achieve target blood pressure. Treatment decisions should be individualized based on baseline blood pressure, therapeutic goals, and patient risk profile.
Pharmacology: This combination contains amlodipine and olmesartan medoxomil. Amlodipine is a calcium channel blocker that inhibits calcium influx into vascular smooth muscle, leading to vasodilation and reduced peripheral resistance. Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, thereby reducing vasoconstriction and aldosterone secretion. Together, they provide a complementary mechanism for effective blood pressure control.
Dosage & Administration: The dose should be individualized based on patient response. The usual starting dose is 5/20 mg once daily for 1–2 weeks, which may be titrated up to a maximum of 10/40 mg once daily as needed. Patients already stabilized on individual components may be switched to the combination. In elderly patients (≥75 years), lower initial doses of amlodipine are recommended, and this combination is generally not suitable as initial therapy.
Interaction: The antihypertensive effect of olmesartan may be reduced when used with NSAIDs, including selective COX-2 inhibitors. Patients receiving such combinations should be monitored for changes in blood pressure, renal function, and electrolyte balance.
Contraindications: Contraindicated in patients receiving aliskiren who have diabetes, due to increased risk of adverse effects.
Side Effects: Common side effects include peripheral edema, headache, dizziness, and flushing. In rare cases, intestinal conditions such as sprue-like enteropathy may occur.
Pregnancy & Lactation: Classified as pregnancy category D. It should not be used during the second and third trimesters due to the risk of fetal harm or death. If pregnancy is detected, the drug should be discontinued immediately. It is unknown whether the components are excreted in breast milk; therefore, a decision should be made whether to discontinue breastfeeding or the medication.
Precautions & Warnings: Use with caution in patients with volume depletion, as it may cause hypotension. Care is required in patients with severe aortic stenosis due to risk of excessive vasodilation. In patients with coronary artery disease, it may increase the frequency or severity of angina or precipitate myocardial infarction.
Use in Special Populations: Safety and efficacy have not been established in pediatric patients. No significant differences in safety have been observed in elderly patients, although dose adjustments may be necessary. There is limited data in patients with renal impairment. Use is not recommended as initial therapy in patients with hepatic impairment.
Overdose Effects: There is no specific information available regarding overdose in humans. Management should be supportive and based on clinical condition.
Therapeutic Class: Combined antihypertensive preparations
Storage Conditions: Store below 30°C, protected from light, and keep out of reach of children.
Similar Products
.jpg)
.jpg)
.jpg)
.jpg)
Previously Browsed Items
.jpg)
.jpg)
.png)
.jpg)
.jpg)
.jpg)
.jpg)
Copyright ﾃつｩ 2026 | Saf1 Rx | All rights reserved